Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 7, 2005. The report details a share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 25, 2005, and discloses changes in directors' interests regarding the GlaxoSmithKline Employee Trust.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback:
- Shares Purchased: 1,095,000 Ordinary shares.
- Purchase Price: 1,370.98 pence per share.
- Total Treasury Holdings: 94,828,000 shares following the transaction.
- Shares in Issue: 5,849,038,302 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 1,095,000 shares on June 6, 2005. Additionally, the GlaxoSmithKline Employee Trust transferred 5,006 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the share repurchase based on the disclosed volume and price.
- Confirm the updated total share count and treasury holdings against subsequent filings.
- Review the impact of the 5,006 share transfer from the GSK Trust on employee option plan liabilities.
- Note that this filing does not contain operational or financial performance data for the period.